Capricor Therapeutics Inc CAPR

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

CAPR hizo una agrupación de acciones (split inverso) de 1:10 el 5 de junio de 2019: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 26 sept

  CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

  Capricor Therapeutics faces a securities class action lawsuit alleging materially misleading statements regarding clinical trial data for its lead drug candidate deramiocel. The company's stock crashed 64% after FDA briefing documents revealed undisclosed modifications to the statistical analysis plan for the HOPE-3 study, which failed to meet pre-specified primary and secondary efficacy endpoints. Investors with losses between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status.

  

• GlobeNewswire Inc. 26 sept

  CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

  Faruqi & Faruqi, LLP is investigating securities fraud claims against Capricor Therapeutics for allegedly making misleading statements about its Deramiocel drug's regulatory prospects. The company allegedly failed to disclose changes to its statistical analysis plan and lack of FDA agreement before resubmitting the Biologics License Application. Capricor's stock plummeted 64% on July 27, 2026, after the FDA released unfavorable briefing documents, and fell an additional 36% on July 30, 2026, following an AdCom panel's 9-3 vote against the drug's efficacy. Investors who purchased securities between December 17, 2025 and July 26, 2026 may be eligible to participate in the class action lawsuit, with a September 28, 2026 deadline to seek lead plaintiff status.

  

• GlobeNewswire Inc. 24 sept

  CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

  Schall, Brown & Schwartz LLP announced a class action securities fraud lawsuit against Capricor Therapeutics for making false and misleading statements regarding its Deramiocel drug candidate. The company allegedly changed its statistical analysis plan without FDA approval before resubmitting its Biologics License Application, creating significant risk of non-approval. The class period spans December 17, 2025 to July 26, 2026, with a September 28, 2026 deadline for investors to participate.

  

• GlobeNewswire Inc. 23 sept

  Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Capricor Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its Deramiocel drug candidate. The complaint claims Capricor changed its statistical analysis plan for clinical data without FDA approval before resubmitting its Biologics License Application, creating significant risk of regulatory rejection. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 are eligible to join the lawsuit.

  

• GlobeNewswire Inc. 22 sept

  Portnoy Law Firm Announces Class Action on Behalf of Capricor Therapeutics, Inc. Investors

  A class action lawsuit has been filed against Capricor Therapeutics on behalf of investors who purchased securities between December 17, 2025 and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for its lead drug candidate Deramiocel without FDA approval, leading to FDA concerns about the validity of clinical results. Following FDA briefing documents released on July 27, 2026, Capricor's stock fell 64%, and after an advisory committee voted 9-3 against the drug's efficacy on July 30, the stock fell an additional 36%.